GlassScriptPhysician profile
Roy R Reeves
NPI 1477564664
$7,918.14
in general payments reported to CMS, 2019-2025
26 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $159 · 2021: $408 · 2022: $1,596 · 2023: $1,697 · 2024: $1,886 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,850 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,849.69 |
| Education | $280.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.94 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,020.52 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $898.02 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $759.64 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $672.50 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $448.51 | 2019-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $417.18 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $366.76 | 2021-2025 | Trintellix |
| Lundbeck LLC | $335.54 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $303.45 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $268.96 | 2023-2025 | Auvelity |
| Allergan, INC. | $132.88 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $131.92 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.67 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $107.80 | 2024-2025 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $104.48 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $102.00 | 2024-2025 | Qelbree |
| Biotronik INC. | $101.18 | 2022 | |
| Indivior INC. | $94.95 | 2022-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $80.18 | 2019-2020 | |
| Shire North American Group INC | $72.05 | 2019 | |
| Collegium Pharmaceutical, INC. | $37.54 | 2025 | Jornay Pm |
| Neuronetics, INC. | $25.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2022 | |
| Alfasigma USA, INC. | $13.94 | 2022 | |
| Bausch Health US, LLC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.